Healthcare Online Education-340 B Elearning


The Need:

The 340b drug pricing program was enacted in 1992 with the goal of allowing eligible participants, or covered entities, to extend scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. As a designated prime vendor, the client conducts live educational programs across the US. Thousands of people attend these programs to learn about the benefits of this program.

Acknowledging the growing demand for information and education about the 340B program, the client wanted to offer online educational resources that could expand the reach of these efforts and help improve program compliance and integrity.

The Solution:

We developed engaging elearning courses that are offered ondemand. The elearning courses explain how 340B can help expand access to needed treatment by shoring up the resources of institutions that provide access and treatment to patients who are uninsured or underinsured. A sleek app-style elearning user interface was designed. The content was presented using an explainer approach using custom designed graphics. Users now have ondemand access to a library of self-paced elearning courses that explain various topics of the drug pricing program.

Features

  • App Style User Interface
  • Explainer Videos
  • Storyline 2
Share

Related Work

Regulatory And Compliance Training- Active Pharmaceutical Ingredient Manufacturer

Regulatory And Compliance Training- Active Pharmaceutical Ingredient Manufacturer

The client is a multinational pharmaceutical company headquartered in India and operations in over 20 countries across the globe. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products. In 2015, the client experienced a significant number of non-compliance escalations in its API manufacturing divisions and specifically

Prescribing Information Interactive for Pharmaceutical Sales Teams

Prescribing Information Interactive for Pharmaceutical Sales Teams

The company is a Fortune 500 rated and world leader in manufacturing and marketing therapeutic drugs. The company markets an anti-cancer drug acting as a selective proteasome inhibitor. The U.S. Food and Drug Administration (FDA) approved the drug on 20 July 2012 for use in patients with multiple myeloma. Three years after FDA approved the expanded use of the

Online Continuing Education for Healthcare Providers

Online Continuing Education for Healthcare Providers

The client, a global leader in rapid diagnostics, joined the White House Antibiotic Stewardship Forum and offered its commitments to support and advance the President’s National Action Plan to Combat Antibiotic-Resistant Bacteria. Forward Eye brings a unique combination of cross-pollinized expertise in the areas of digital learning, digital marketing and digital enterprise solutions. Forward Eye consulted the client